China vaccines industry valued at around $2.3 billion in 2009

5 October 2010

As one of the world's largest vaccine producers, China not only has many vaccine companies, various vaccine categories and a large quantity, but also the country’s human and animal vaccine enterprises are in general separated, according to a new report from ResearchInChina.

At the end of 2009, there were around 38 human vaccine manufacturers and 54 animal vaccine producers that had passed CMP certification in China. With the development of the national economy and people’s growing awareness of precautionary measures, the scale of the Chinese vaccine market has increased continuously, with a CAGR of 21.5% during 2007-2009. In addition, China’s vaccine market reached a value of 15.2 billion renminbi ($2.27 billion) in 2009, of which around 9 billion renminbi was human vaccines and 6.2 billion renminbi or so of animal vaccines.

Sector involves high risk, investment and profit

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical